UK Maritime Trade Operations on the 15th forwarded a Combined Maritime Information Centre bulletin saying the US military blockade of Iranian ports remains in effect.

Rongchang Biotech (09995.HK) said its in‑house novel bispecific antibody RC148 has dosed the first patient in the randomized, multicenter Phase II/III trial RC148‑C303 testing RC148 plus chemotherapy as first‑line treatment for unresectable or metastatic colorectal cancer (CRC). The study will evaluate efficacy and safety of the combination.

Iran’s deputy foreign minister Gharibabadi said the Islamabad memorandum (an Iran–U.S. understanding) has been finalized and will be signed in Switzerland on June 19. He said two measures take effect immediately from this morning: an immediate, permanent end to hostilities on all fronts, including Lebanon, and the U.S. lifting and terminating its maritime blockade of Iran. Iranian commitments will begin on signing; after a ceasefire, U.S. lifting of the blockade and frozen Iranian assets begin to thaw, both sides will enter a 60‑day negotiation period to finalise an agreement covering nuclear issues, U.S. sanctions relief, reconstruction of Iran’s economic mechanisms and verification arrangements. Gharibabadi warned Iran will respond if the other side defaults and said Iranian forces remain “finger on the trigger.” Iran’s Supreme National Security Council will issue a related statement; Iran said its gains far exceed its commitments.